Table 2.
Top-line probabilistic results from a 3-year analysis of the cost-effectiveness of prolonged-release (PR) versus immediate-release (IR) tacrolimus in liver transplant recipients in the UK
| IR tacrolimus (Prograf®) | PR tacrolimus (Advagraf®) | Difference | |
|---|---|---|---|
| Cost of immunosuppression, £ | 10,405 (2203) | 9469 (2006) | −937 (208) |
| Cost of retransplantation, £ | 1654 (443) | 949 (689) | −705 (820) |
| Total cost, £ | 12,062 (2245) | 10,420 (2130) | −1642 (885) |
| Life expectancy, months | 30.62 (0.09) | 31.52 (0.22) | +0.89 (0.23) |
| Graft life expectancy, months | 30.16 (0.09) | 31.23 (0.19) | +1.07 (0.21) |
| Annualized probability of graft loss | 0.064 | 0.039 | −0.025 |
| NNT to avoid graft loss with PR vs. IR tacrolimus | 14 | ||
| Annualized probability of death | 0.058 | 0.039 | −0.019 |
| NNT to avoid death with PR vs. IR tacrolimus | 18 | ||
Values are presented as mean (standard deviation)
£ 2014 pounds sterling, IR immediate-release, NNT number needed to treat, PR prolonged-release